Rheumatological complications from cancer immunotherapy, particularly immune checkpoint inhibitors, are increasingly recognized in clinical practice, affecting approximately 5-10% of patients. These complications include inammatory arthritis, myositis, Sjögren's syndrome, vasculitis, and lupus-like syndromes. The pathophysiology involves enhanced T-cell activation leading to autoimmunity. Clinical manifestations vary widely and require thorough evaluation. Diagnosis relies on patient history, physical examination, laboratory tests, imaging, and biopsy. Treatment involves NSAIDs, corticosteroids, and DMARDs, tailored to severity. Multidisciplinary collaboration is crucial for optimal management.